Amcli ETS / Articles posted by giuseppe giocoli (Page 338)
  • Sort Blog:
  • All
  • Batteriologia
  • Malattie da prioni
  • Terapie antinfettive
  • Farmaci antinfiammatori
  • Malattie delle articolazioni
  • Malattie ortopediche
  • Micologia
  • Immunologia
  • Tossicodipendenza
  • Sepsi neonatale
  • inflammatory bowel disease (IBD)
  • Infezioni urinarie
  • Infezioni associate all'assistenza sanitaria
  • Veterinaria
  • Prevenzione
  • Sepsi
  • Febbre
  • Malattie dell'occhio
  • Parassitologia
  • Infezioni atipiche
  • Marcatori d'infezione
  • Varie
  • Terapie palliative
  • Virologia
  • Zoonosi
  • Problemi diagnostici
  • Microbioma
  • Farmacologia
  • Antibiotici
  • Test diagnostici
  • Trapianti d'organo o tessuti
  • Neoplasie
  • Eziologia
  • Micobatteriologia
  • Tossinfezioni alimentari
  • Tecnologia
  • Metagenomica
  • Malattie respiratorie
  • Avvisi ai lettori
  • Fagi
  • Intossicazione alimentare
  • Malattie Tropicali
  • Malattie infiammatorie
  • Ultime notizie
  • antimicotici
  • Genomica
  • Malattie Metaboliche
  • Nutrizione
  • Mal. a trasm. sessuale
  • Medicina ambientale
  • Semeiotica
  • Probiotici
  • Tossicologia
  • Linee guida - Raccomandazioni
  • Epidemie infettive
  • Eruzioni mucocutanee da infezione
  • Marcatore
  • Malattie cardiocircolatorie
  • Vaccinazioni
  • Prognosi delle infezioni
  • Malattie dermatologiche
  • Oculistica
  • Malformazioni congenite
  • Argomento generico
  • Disinfezione
  • Oncologia
  • Malattie genetiche
  • Malattie renali
  • Problemi metodologici
  • Necrologio
  • Flogosi acute o croniche
  • Malattie da infezione
  • Politica sanitaria
  • Malattie del viaggiatore
  • Patogenesi
  • Malnutrizione
  • Tossinfezion alimentari
  • Squilibri ormonali
  • Uncategorized
  • Malattie da prioni4
  • Rickettsie
  • Fattori di rischio
  • Malattie neurologiche
  • Malattie autoimmuni
Agosto 4, 2021

Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study

Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study by Meng-Rui Lee,Hung-Ling Huang,Li-Ta Keng,Hsu-Liang Chang,Chau-Chyun Sheu,Pin-Kuei Fu,Jann-Yuan Wang,Inn-Wen Chong,Jin-Yuan Shih andChong-Jen YuJ. Fungi2021, 7(6), 480; https://doi.org/10.3390/jof7060480 – 12 Jun 2021Viewed by 718Abstract Objectives: Aspergillus-specific IgG (Asp-IgG) cut-off level in diagnosing chronic pulmonary aspergillosis (CPA) remains unknown. Methods: We prospectively recruited participants with clinical suspicion of CPA in three centers in Taiwan during 2019 June to 2020 August. Serum Aspergillus fumigatus-specific IgG […] Read more.(This article belongs to the Special Issue Respiratory Fungal Infections)

By giuseppe giocoli
Agosto 4, 2021

Candida albicans and Oral Carcinogenesis

Candida albicans and Oral Carcinogenesis. A Brief Review by Michele Di Cosola,Angela Pia Cazzolla,Ioannis Alexandros Charitos,Andrea Ballini,Francesco Inchingolo andLuigi SantacroceJ. Fungi2021, 7(6), 476; https://doi.org/10.3390/jof7060476 – 12 Jun 2021Cited by 1 | Viewed by 543Abstract Current medical knowledge and research on patients’ management are still evolving, and several protocols on minimizing risk of infection by Candida spp. among the population have developed. The aim of this work is to review the epidemiological and biomolecular characteristics and the various […] Read more.(This article belongs to the Special Issue Fungal Research in Dental Infection, Immunity and Inflammation)

By giuseppe giocoli
Agosto 4, 2021

Genetic Manipulation as a Tool to Unravel Candida parapsilosis Species Complex Virulence and Drug Resistance: State of the Art

Genetic Manipulation as a Tool to Unravel Candida parapsilosis Species Complex Virulence and Drug Resistance: State of the Art by Marina Zoppo,Noemi Poma,Mariagrazia Di Luca,Daria Bottai andArianna TavantiJ. Fungi2021, 7(6), 459; https://doi.org/10.3390/jof7060459 – 07 Jun 2021Viewed by 623Abstract An increase in the rate of isolation of Candida parapsilosis in the past decade, as well as increased identification of azole-resistant strains are concerning, and require better understanding of virulence-like factors and drug-resistant traits of these species. In this regard, the present review […] Read more.(This article belongs to the Special Issue Interplay between Antifungal Resistance and Virulence: Potential Novel Targets and Therapeutic Strategies)

By giuseppe giocoli
Agosto 4, 2021

Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment

Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment by José María Valle-T-Figueras,Berta Renedo Miró,Maria Isabel Benítez Carabante,Cristina Díaz-de-Heredia,Jaume Vima Bofarull,Natalia Mendoza-Palomar,Maria Teresa Martín-Gómez andPere Soler-PalacínJ. Fungi2021, 7(6), 456; https://doi.org/10.3390/jof7060456 – 07 Jun 2021Viewed by 524Abstract Voriconazole plasma concentrations (PC) are highly variable, particularly in children. Dose recommendations in 2–12-year-old patients changed in 2012. Little data on therapeutic drug monitoring (TDM) after these new recommendations are available. We aimed to evaluate voriconazole monitoring in children with invasive fungal infection […] Read more.(This article belongs to the Special Issue Pediatric Fungal Infections: Diagnostic and Therapeutic Aspects)

By giuseppe giocoli
Agosto 4, 2021

Paediatric Histoplasmosis 2000–2019: A Review of 83 Cases

Paediatric Histoplasmosis 2000–2019: A Review of 83 Cases by Rebecca MacInnes andAdilia WarrisJ. Fungi2021, 7(6), 448; https://doi.org/10.3390/jof7060448 – 04 Jun 2021Viewed by 520Abstract Histoplasmosis is an endemic fungal infection that is confined to specific geographical regions. Histoplasma spp. are primary pathogens that cause disease in both immunocompetent and immunocompromised patients, ranging from a single-organ (mostly affecting the lungs) infection to life-threatening disseminated disease.  Histoplasmosis was first described in a paediatric patient in 1934, almost 30 years after the first adult patient with fatal disseminated histoplasmosis was described by Samuel Darling in 1906 [1,2]. Histoplasmosis is caused by the dimorphic fungus Histoplasma capsulatum, which can be divided into two varieties: H. capsulatum var. capsulatum and H. capsulatum var. duboisii [3]. H. capsulatum var. duboisii is found in Africa, whereas H. capsulatum var. capsulatum is most prevalent in the other endemic regions [4]. In addition to the traditional endemic regions, including the Ohio and Mississippi River Valleys in the United States, Central and South America and Africa, the true global distribution of histoplasmosis has recently been reported to be much more widespread [5]. Seroprevalence data and epidemiological studies from South-East Asia (in particular Thailand), Queensland and New South Wales in Australia, the Po Valley area in Italy, Quebec and Ontaria in Canada and an increased number of states in the United States show that histoplasmosis is endemic across the world [5]. Histoplasma conidia are found in these geographic areas in soil contaminated with bird and bat guano. Activities disturbing the soil lead to the release of the infectious conidia into the air, with infection acquired by inhaling contaminated air.

By giuseppe giocoli
Agosto 4, 2021

SCA Medium: A New Culture Medium for the Isolation of All Candida auris Clades

SCA Medium: A New Culture Medium for the Isolation of All Candida auris Clades by Ahmad Ibrahim,Lucie Peyclit,Rim Abdallah,Saber Khelaifia,Amanda Chamieh,Jean-Marc Rolain andFadi BittarJ. Fungi2021, 7(6), 433; https://doi.org/10.3390/jof7060433 – 29 May 2021Viewed by 730Abstract Candida auris is an emerging multidrug-resistant yeast causing nosocomial infections and associated with high mortality in immunocompromised patients. Rapid identification and characterisation are necessary for diagnosis and containing its spread. In this study, we present a selective culture medium for all C. auris[…] Read more.(This article belongs to the Special Issue Candida auris 2.0)

By giuseppe giocoli
Agosto 4, 2021

Treatment and Prevention of Histoplasmosis in Adults Living with HIV

Treatment and Prevention of Histoplasmosis in Adults Living with HIV by David S. McKinseyJ. Fungi2021, 7(6), 429; https://doi.org/10.3390/jof7060429 – 28 May 2021Viewed by 708Abstract Histoplasmosis causes life-threatening disseminated infection in adult patients living with untreated HIV. Although disease incidence has declined dramatically in countries with access to antiretroviral therapy, histoplasmosis remains prevalent in many resource-limited regions. A high index of suspicion for histoplasmosis should be maintained in […] Read more.(This article belongs to the Special Issue Histoplasma and Histoplasmosis 2020)

By giuseppe giocoli
Agosto 4, 2021

Successful Treatment of Cryptococcal Meningitis and Cryptococcoma with Isavuconazole in a Patient Living with HIV

Successful Treatment of Cryptococcal Meningitis and Cryptococcoma with Isavuconazole in a Patient Living with HIV by Brendan O’Kelly,Aia Mohamed,Colm Bergin,Fiona Lyons,Thomas R. Rogers,Brian O’Connell andEmma DevittJ. Fungi2021, 7(6), 425; https://doi.org/10.3390/jof7060425 – 28 May 2021Viewed by 728Abstract We describe the successful use of isavuconazole for treatment of an HIV-positive patient with cryptococcal meningitis following induction therapy with liposomal amphotericin B and flucytosine. Because the Cryptococcus neoformans isolate from cerebrospinal fluid had a borderline minimum inhibitory concentration of 8 mg/L, initial […] Read more.

By giuseppe giocoli
Agosto 4, 2021

Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans—In Silico, In Vitro and In Vivo Approaches

Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans—In Silico, In Vitro and In Vivo Approaches by André L. S. Santos,Lys A. Braga-Silva,Diego S. Gonçalves,Lívia S. Ramos,Simone S. C. Oliveira,Lucieri O. P. Souza,Vanessa S. Oliveira,Roberto D. Lins,Marcia R. Pinto,Julian E. Muñoz,Carlos P. Taborda andMarta H. BranquinhaJ. Fungi2021, 7(6), 424; https://doi.org/10.3390/jof7060424 – 28 May 2021Viewed by 816Abstract The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen Candida albicans by using in silico, in vitro and in vivo […] Read more.

By giuseppe giocoli

Associazione Microbiologi Clinici Italiani ETS
N. 26168 Iscrizione RUNTS
Via C. Farini 81
20159 Milano
C.F.06653690153
P.I. 12404560158

USER MENU

Accedi al sito AMCLI

 

 

Accedi Eventi FAD

CONTATTACI

AMCLI ETS - Via Farini 81
20159 Milano (MI)
Tel +39 02 66801190
Fax +39 02-69001248
cellulare 335 5900868
E-mail segreteriaamcli@amcli.it

Privacy Policy

© Copyright AMCLI 2015 - All rights reserved - Designed by glueglue™